LRRK2 Drug Trial Shares Promising Results, Company to Begin Second Study | Parkinson's Disease
Last night, the biotech company conducting the first-ever clinical trial of a Parkinson's treatment targeting LRRK2 announced good news. This early study has reported positive results, showing that the experimental treatment is safe and exerts the desired effect in body cells, setting the stage for future trials. Clinical testing will continue in patients who carry the LRRK2 mutation. The company's CEO has been forthcoming with his acknowledgment of our Foundation's partnership in helping bring LRRK2 to this point.
LRRK2 is one of the most promising targets in Parkinson's disease, with potential to slow or stop progression of the disease (something no current treatment can do). It has been the subject of intensive investigation fieldwide, and millions of dollars in grants from our Foundation, since its discovery in 2004.
It is our privilege to share this news with you, the patients and families relying on us to drive meaningful progress in Parkinson's research. Your commitment to our mission makes it possible for us to work with the researchers on the front lines of accelerating the breakthroughs patients need. Please consider making a gift, or renewing your support, today. Thank you for all you do.
With warmest wishes for a joyous holiday season and a bright New Year,
The Michael J. Fox Foundation for Parkinson's Research